Alzheimer’s May Shrink Two Brain Regions a Decade Before Memory Loss
Alzheimer’s disease may start reshaping the brain far earlier than doctors have been able to see. Researchers at Johns Hopkins University have found that two regions — the entorhinal cortex and the amygdala — begin losing tissue up to a decade before memory problems appear, and earlier than the hippocampus, the structure doctors usually examine first. The finding, published in NeuroImage Reports and presented at Neuroscience 2026, could give doctors a much earlier warning sign — and a chance to treat people before symptoms take hold.
Two regions flagged before the hippocampus
The team analysed hundreds of MRI and PET scans drawn from two long-running research programmes: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. The scans covered people at every stage of the disease, from those with no symptoms to people with cognitive impairment and patients who later died from Alzheimer’s.
Across both groups the pattern held: the entorhinal cortex and the amygdala showed greater relative tissue loss in the early stages than the hippocampus. The entorhinal cortex helps retrieve stored memories, while the amygdala processes emotional memory — two functions that falter early in the disease.
“We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms,” said Michael Miller, a biomedical engineer at Johns Hopkins and the study’s senior author. “It’s at least a 5-to-10-year play where your brain is changing.”
Tau tangles track the shrinkage
PET imaging showed the shrinkage overlapping with regions where tau, the protein that forms damaging tangles in Alzheimer’s, had built up. Digital pathology work confirmed the link, tying the early tissue loss directly to the abnormal protein accumulation that drives the disease.
The researchers plan to dig deeper into the biology around those tau changes. “Our future work is to better show the molecular neighborhoods associated with these Tau protein changes as localized by these clinical biomarkers of atrophy,” Miller said.
The pattern could also sharpen how doctors judge risk. “This could really play into better risk stratification for identifying who is going to have cognitive decline in the near future — and treating people earlier and earlier to hopefully slow the course of the disease,” said Meaghan Morris, a co-author and neuropathologist who studies Alzheimer’s and other dementias.
Why an earlier warning matters
For Marilyn Albert, director of the Johns Hopkins Alzheimer’s Disease Research Center and a co-author, the point of the work is treatment before symptoms. Her aim, she said, is to be able to treat people before Alzheimer’s symptoms develop, so that decline may be delayed or even stopped.
The researchers are clear about the limits, however. The finding points to promising early biomarkers, but it does not yet establish a clinical test that can predict Alzheimer’s years in advance. More validation is needed before scans of these two regions could be used as a routine diagnostic tool.
The work lands as brain health draws a run of attention — from a Harvard headset that checks for concussion on the sidelines to new funding for research, after California voters approved $8.4 billion in medical research funding. In a separate strand of research, Stanford Medicine scientists have developed a connectivity score, based on resting-state brain scans, that tracks who is most likely to decline — another sign that the field is moving towards spotting risk years before symptoms appear.
The research was announced through EurekAlert, which carried the university’s account of the study. Independent coverage of the study appeared on 15 November.